|
1) http://www.jgca.jp/PDFfiles/MLguidline0.pdf
|
|
|
|
|
2) 渡辺英伸, 丸田和夫, 味岡洋一, 他. 消化管悪性リンパ腫の臓器特異性—病理学的見地から. 胃と腸. 1988; 33: 299-308
|
|
|
|
|
3) Jaffe ES, Harris NL, Stein H, et al. World Health Organization Classification of Tumours; Tumours of heamatopoietic and lymphoid tissues. Lyon: IARC Press; 2001
|
|
|
|
|
|
4) Wotherspoon AC, Diss TC, Pan L, et al. Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori. Lancet. 1993; 342: 575-7
|
|
|
|
|
5) Toracchio S, Ota H, Wotherspoon A, et al. Translocation t(11; 18)(q21; q21) in gastric B-cell lymphomas. Cancer Science. 2009; 100: 881-7
|
|
|
|
|
|
6) Rohatiner A, d'Amore F, Coiffier B, et al. Report on a workshop convened to discuss the pathological and staging classifications of gastrointestinal tract lymphoma. Ann Oncol. 1994; 5: 397-400
|
|
|
|
|
|
7) The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med. 1993; 329: 987-94
|
|
|
|
|
|
8) Peura DA. The report of the digestive health initiative international update conference on Helicobacter pylori. Gastroenterology. 1997; 113: S4-8
|
|
|
|
|
|
9) The European Helicobacter pylori Study Group(EHPSG). Current European concepts in the managements of Helicobacter pylori infection; the Maastrict consensus report. Gut. 1997; 41: 8-13
|
|
|
|
|
|
10) Schechter NR, Portlock CS, Yahalom J. Treatment of mucosa-associated lymphoid tissue lymphoma of the stomach with radiation alone. J Clin Oncol. 1998; 16: 1916-21
|
|
|
|
|
|
11) 深川剛生, 佐野 武. 外科疾患データブック. 消化管 胃悪性リンパ腫. 外科. 2007; 69: 1425-9
|
|
|
|
|
12) McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998; 16: 2825-33
|
|
|
|
|
|
13) Vose JM, Link BK, Grossbard ML, et al. Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. J Clin Oncol. 2001; 19: 389-97
|
|
|
|
|
|
14) Kodera Y, Yamamura Y, Nakamura S, et al. The role of radical gastrectomy with systematic lymphadenectomy for the diagnosis and treatment of primary gastric lymphoma. Ann Surg. 1998; 227: 45-50
|
|
|
|
|
|
15) Koch P, Probst A, Berdel WE, et al. Treatment results in localized primary gastric lymphoma: data of patients registered within the German multicenter study (GIT NHL 02/96). J Clin Oncol. 2005; 23: 7050-9
|
|
|
|
|
|
16) Miller TP, Dahlberg S, Cassady JR, et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. N Engl J Med. 1998; 339: 21-6
|
|
|
|
|
|
17) Pfreundschuh M, Trümper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomized controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006; 7: 379-91
|
|
|
|
|
|
18) Miller TP, Unger JM, Spier C. Effect of adding rituximab to three cycles of CHOP plus invoved-field radiotherapy for limited-stage aggressive diffuse B-cell lymphoma (SWOG-0014). Blood. 2004; 104: 158a
|
|
|
|
|
|
19) http://www.nccn.org/professionals/physician_gls/PDF/nhl.pdf
|
|
|
|
|
|
20) Fisher RI, Miller TP, O'Connor OA. Diffuse aggressive lymphoma. Hematology. 2004; 1: 221-36
|
|
|
|
|
|
21) Coiffier B. State-of-the-art therapeutics: diffuse large B-cell lymphoma. J Clin Oncol. 2005; 23: 6387-93
|
|
|
|
|
|
22) Ferrucci PF, Zucca E. Primary gastric lymphoma pathogenesis and treatment: what has changed over the past 10 years？ Br J Haematol. 2007; 136: 521-38
|
|
|
|
|
|
23) Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002; 346: 235-42
|
|
|
|
|
|
24) 横山雅大, 照井康仁, 畠 清彦. Hematologic Malignancies/Pediatric Malignancies造血器腫瘍 再発・治療抵抗性造血器腫瘍の治療の現況 R-CHOP療法抵抗性B細胞リンパ腫の治療. 癌と化学療法. 2008; 35: 766-70
|
|
|
|
|
|
25) Krishnan A, Nademanee A, Fuug HC, et al. Phase II trial of a transplantation regimen of yttrium-90 ibritumomabtiuxetan and high-dose chemotherapy in patients with non-Hodgkin's lymphoma. J Clin Oncol. 2008; 26: 90-5
|
|
|
|
|